Released May 6, 2016, before the open
10-Q filed May 9, 2016, 39 days after period end · 0001493152-16-009551
Q1 2016 · 10-Q
Revenue$5.48M$5.48M −4.3% vs Q1 2015−15.9% vs Q4 2015
Net Income-$1.04M-$1.04M N/M vs Q1 2015N/M vs Q4 2015
EPS Diluted-$0.57-$0.57 N/M vs Q1 2015no prior Q4 2015 on file
Operating Income-$868,000N/M
Operating Cash Flow-$504,000N/M
Free Cash Flowderived-$681,000N/M
Margins · derived
Operating margin-15.8%+22.7 pt vs Q1 2015
Net margin-19.0%+20.5 pt vs Q1 2015
What the release said
The release
Same quarter
| Metric | Q1 2016 | Q1 2015 | Q1 2014 | Q1 2013 |
|---|---|---|---|---|
| Revenue | $5.48M | $5.73M | $6.42M | $6.12M |
| Net Income | -$1.04M | -$2.26M | -$649.00K | -$369.00K |
| EPS Diluted | -$0.57 | -$0.02 | -$0.01 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR